Zai Lab announced positive preliminary first-in-human results from the
single-dose escalation portion of the global Phase 1/1b study of ZL-1503, a
long-acting IL-13/IL-31 receptor‑α bispecific antibody for atopic dermatitis.
The company said the profile could support reduced dosing frequency. Results
will be presented at the ACAAI 2026 annual scientific meeting.